Skip to main content

Table 3 Proportion of patients stratified by treatment group (“concomitant LABA and ICS users”, “Switchers”, “non-concomitant LABA and ICS users”, “LABA users without ICS”, “ICS users without LABA”) for the years 2004 to 2008

From: Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial

  Year
  2004 2005 2006 2007 2008
Concomitant LABA and ICS users 123,873 (52.0%) 152,857 (54.6%) 152,418 (53.3%) 172,225 (55.3%) 177,159 (57.6%)
Switchers 12,785 (5.4%) 13,266 (4.7%) 14,207 (5.0%) 14,446 (4.6%) 14,899 (4.8%)
Non-concomitant LABA and ICS users 1,314 (0.6%) 1,686 (0.6%) 1,992 (0.7%) 1,896 (0.6%) 1,936 (0.6%)
LABA users without ICS 15,612 (6.5%) 19,200 (6.9%) 18,193 (6.4%) 17,810 (5.7%) 16,749 (5.4%)
ICS users without LABA 84,818 (35.6%) 92,970 (33.2%) 99,334 (34.7%) 105,252 (33.8%) 96,615 (31.4%)